Skip to content
lifestyle.massnews.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Marengo Therapeutics
Marengo Presents Interim Phase 2 STARt-002 Results for First-in-Class Selective T-Cell Agonist Invikafusp Alfa Plus Sacituzumab Govitecan Across Two Metastatic Breast Cancer Cohorts in Oral Presentation at SITC 2026
November 9, 2026
Marengo Therapeutics Announces Landmark Nature Medicine Publication Establishing First-in-Human Proof of Vβ-Directed T-Cell Biology and Antitumor Activity
October 23, 2026
Marengo Therapeutics Presents Phase 2 STARt-001 Results at ESMO 2026 Demonstrating Tissue-Agnostic Single-Agent Activity of Invikafusp Alfa in TMB-H Solid Tumors Mostly Unresponsive to Immune Checkpoint Blockade
October 23, 2026
Marengo Therapeutics Receives Second U.S. FDA Fast Track Designation for Invikafusp Alfa, Expanding to a Tissue-Agnostic Indication Across Tumor Mutational Burden-High Solid Tumors That Progress After Prior Therapy, Including Checkpoint Inhibition
October 18, 2026
Interim Phase 2 Results from First-in-Class Combination of Invikafusp Alfa and TRODELVY® Selected for Oral Presentation at SITC 2026
October 7, 2026
Marengo Therapeutics Completes Enrollment in Phase 1/2 STARt-001 Monotherapy Cohorts and Strengthens Leadership to Advance Invikafusp Alfa Toward Late-Stage Development
September 9, 2026
Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion
August 4, 2026
Marengo Secures ESMO 2026 Oral Presentation for Key Phase 2 Invikafusp Alfa Data in PD-1-Resistant Solid Tumors and Appoints Pembrolizumab Development Leader Eric Rubin, M.D., to Scientific Advisory Board
July 20, 2026